John Higgins Buys Shares of OmniAb, Inc.

John Higgins, an insider at OmniAb, Inc., purchased 40,000 shares of the company's stock on June 17, 2026. This insider transaction did not specify a purchase price, and it's part of ongoing activity among company insiders.

Other Institutional Activity in OmniAb

BlackRock, Inc. increased its holdings in OmniAb by 41,900 shares, bringing its total to 8,106,881 shares valued at approximately $12.7 million. Geode Capital Management, LLC also added to its position, acquiring 202,887 shares, ending with 2,925,579 shares worth about $4.59 million. Conversely, Cadian Capital Management, LP reduced its stake by 277,825 shares, now holding 4,157,129 shares valued at $6.53 million.

OmniAb, Inc. Stock Snapshot

Shares of OmniAb, Inc. (NASDAQ: OABI) traded near $2.34. The company has a market cap of approximately $339.2 million and a beta of 1.146, indicating moderate volatility. Over the past year, the stock has seen a low of $1.30 and a high of $2.79. The 50-day moving average is $1.97, while the 200-day moving average stands at $1.80. OmniAb maintains a strong liquidity position with a current ratio of 4.801 and a quick ratio of 4.549.

Recent Earnings

OmniAb reported revenue of $28.94 million, showing a growth of 2.47%. However, the company is not profitable, with a net margin of -187.59% and a return on equity of -20.25%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at OmniAb, Inc.

In addition to John Higgins, several other insiders were active on June 17, 2026. Jennifer Cochran bought 40,000 shares and sold 20,000 shares, while Carolyn Bertozzi acquired 60,000 shares and sold 20,000 shares. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on OmniAb. HC Wainwright & Co. reiterated its buy rating with an $11.00 price target on March 19, 2025. Benchmark maintained its buy rating with a $6.00 target on March 20, 2025. The consensus target price among analysts is $7.33, based on six opinions.

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company based in Emeryville, California. It licenses technology for discovering therapeutics to pharmaceutical and biotech companies worldwide. The company’s platform uses engineered transgenic animals to screen and create diverse antibody repertoires, aiding in drug development. OmniAb's CEO is Matthew W. Foehr, and the company employs about 89 people.

Bottom Line

John Higgins' recent purchase of OmniAb shares highlights ongoing insider interest in the company. Investors keep an eye on such insider activities as potential indicators of confidence in the company's prospects. Remember, insider transactions are disclosed after the fact and may not reflect current positions.